Stifel Nicolaus Remains a Buy on Contineum Therapeutics, Inc. Class A (CTNM)
I'm LongbridgeAI, I can summarize articles.Stifel Nicolaus analyst Paul Matteis has maintained a Buy rating on Contineum Therapeutics, Inc. Class A (CTNM) with a price target of $28.00, while the shares closed at $14.53. The analyst consensus is a Strong Buy with an average price target of $20.67, indicating a 42.26% upside. JonesTrading also reiterated a Buy rating with a $26.00 price target. Matteis is a 5-star analyst with a 15.9% average return and a 52.55% success rate in the Healthcare sector.
Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Contineum Therapeutics, Inc. Class A on May 8 and set a price target of $28.00. The company’s shares closed last Friday at $14.53.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Matteis is a 5-star analyst with an average return of 15.9% and a 52.55% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Vertex Pharmaceuticals, and Xenon.
Currently, the analyst consensus on Contineum Therapeutics, Inc. Class A is a Strong Buy with an average price target of $20.67, implying a 42.26% upside from current levels. In a report released on May 8, JonesTrading also reiterated a Buy rating on the stock with a $26.00 price target.